Metagenomi Therapeutics, Inc.
Metagenomi Therapeutics, Inc. (MGX): 1 pipeline candidate · ~20 mo cash runway. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
19.7 months
D/E 0.43 · 0% dilution
Lead: Preclinical
1 candidate
N/A
0 buys · 6 sells (180d)
A transparent, data-derived signal for Metagenomi Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$44.4M
Cash
$29.7M
Quarterly Burn
$21.2M
Runway
19.7 mo
Revenue
$1.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| hemophilia a program | Preclinical |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
46
Total value held
$8.7M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 2,115,888 | $2.8M |
| renaissance technologies llc | 787,900 | $1.1M |
| two sigma investments, lp | 496,767 | $666K |
| bridgeway capital management, llc | 395,800 | $530K |
| jacobs levy equity management, inc | 382,153 | $512K |
| geode capital management, llc | 358,200 | $480K |
| pura vida investments, llc | 264,391 | $354K |
| blackrock, inc. | 230,134 | $308K |
| wells fargo & company/mn | 202,138 | $271K |
| vanguard fiduciary trust co | 170,174 | $228K |
Showing top 10 of 46 institutional holders of Metagenomi Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Metagenomi Therapeutics, Inc.'s pipeline?
Metagenomi Therapeutics, Inc. (MGX) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Metagenomi Therapeutics, Inc.'s lead drug candidate?
Metagenomi Therapeutics, Inc.'s most advanced tracked candidate is hemophilia a program (Preclinical) for Hemophilia A.
What is Metagenomi Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Metagenomi Therapeutics, Inc. has approximately 19.7 months of cash runway.
What is Metagenomi Therapeutics, Inc.'s market capitalization?
Metagenomi Therapeutics, Inc.'s market capitalization is approximately $44.4M.
Who is the CEO of Metagenomi Therapeutics, Inc.?
Dr. Jian Irish M.B.A., Ph.D. is the chief executive officer of Metagenomi Therapeutics, Inc. (MGX).
Get the full picture on Metagenomi Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.